INTRODUCTION
Trace minerals, including iron and zinc, are essential cofactors for hundreds of proteins and enzymes. These metallo-proteins and -enzymes function in a vast array of critical biological processes, including oxygen delivery, amino acid metabolism, collagen synthesis, sexual maturation, and cell growth and differentiation. 1, 2 To confer biological function or to be stored for later use, trace minerals must be consumed in the diet, absorbed, and delivered to the appropriate target tissue.
Membrane transporters serve as gatekeepers of trace mineral metabolism by controlling uptake and efflux from cells and organelles. Thus, membrane transporters play a critical role in processes such as nutrient uptake and excretion, ion homeostasis, and signal transduction. Failure to regulate transport can result in metal deficiency or toxicity and lead to disease. For example, mutations in the gene encoding the intestinal zinc importer ZIP4 result in zinc deficiency and manifest as a rare and potentially fatal skin disease, acrodermatitis enteropathica. 3, 4 Conversely, iron overload in the form of ferroportin disease results from mutations in the gene encoding the iron exporter ferroportin. 5 Importantly, iron and zinc homeostasis is primarily regulated at the point of uptake, emphasizing the critical nature of cellular uptake mechanisms in maintaining trace mineral homeostasis. Mechanisms conferring transcriptional and posttranscriptional control of trace mineral transporters have been well described (reviewed in Muckenthaler et al. 6 and Andrews et al. 7 ). As compared to transcriptional regulation, post-translational modification enables trace mineral transporters to more rapidly adapt to cellular and systemic signals to homeostatically regulate ion transport. 8 Increasing evidence suggests that ubiquitination is a common post-translational regulatory mechanism for the degradation of zinc, iron, manganese, copper, and other trace mineral transporters. The recent discovery of a novel ubiquitin-mediated degradation pathway of the trace mineral transporter ZIP14 suggests that there is much to be discovered in this emerging area. This review will update the current state of knowledge on the ubiquitination of proteins known to transport iron and zinc and will discuss the potential utility of post-translational modification of trace mineral transporters in the treatment of disease.
IRON AND ZINC TRANSPORTERS
Significant advances have been made over the past decade in the identification and regulation of trace mineral transporters. Table 1 9-24 includes the characteristics of ubiquitinated iron and zinc transporters. All belong to the SLC (solute carrier) superfamily. Each transporter is named with the root symbol SLC followed by a numeral identifying the family and a letter identifying the subfamily. Zinc transporters can be divided into 2 distinct families: the SLC39 or Zrt-, irt-like protein (ZIP) family of zinc importers, and the SLC30 or Zn Transporter (ZnT) family of zinc exporters (members of the ZIP family function to import zinc into the cytosol, and members of the ZnT family export zinc from the cytosol). Expression and localization of zinc transporters is cell and tissue specific, and increasing evidence suggests that the function of the expressed transporters is unique to the cell type.
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SLC11A1 and SLC11A2 encode the iron importers natural resistance-associated macrophage protein-1 (NRAMP1) and divalent metal transporter-1 (DMT1), respectively, and SLC40A1 encodes the iron exporter ferroportin. NRAMP1 is found in the phagolysosomes of macrophages and neutrophils, 26, 27 and DMT1 is primarily expressed on the apical membrane of duodenal enterocytes. 28, 29 Both function to import iron with high affinity and, possibly, other divalent metals (e.g., zinc, manganese, copper, cadmium, cobalt, nickel, and lead) into the cytosol. 28, 30 Conversely, ferroportin is highly expressed in the duodenum, where it functions to export iron, [31] [32] [33] and manganese with less affinity, 34, 35 from the cell.
REGULATION OF IRON AND ZINC TRANSPORTERS Transcriptional and post-transcriptional regulation
Traditionally, trace mineral transport was thought to be regulated primarily at the transcriptional and posttranscriptional level. Transcriptional regulation of trace mineral transporters occurs through metal-responsive transcription factors, which can bind to regulatory elements in the promoter region of DNA to influence transcription of a target gene. For example, metal response element-binding transcription factor-1 (MTF-1) protects cells against zinc toxicity by regulating the expression of metallothionein and ZnT1. 36 When iron is limited, iron regulatory proteins bind iron regulatory elements (IREs) in the 5 0 -untranslated regions of mRNA to block translation of proteins involved in iron metabolism (both DMT1 and ferroportin genes have IRE motifs). Iron regulatory proteins binding to IREs in the 3 0 -untranslated region stabilize the mRNA and prevent degradation. However, transcriptional regulation of trace mineral transport is relatively slow and requires significant amounts of energy compared with other regulatory mechanisms. 8, 37 In contrast, post-translational mechanisms exist to enable rapid and dynamic adjustments of protein levels, which are particularly important when monitoring nutrient transport.
Post-translational modification: ubiquitination. Posttranslational modification is a mechanism by which trace mineral transporters can rapidly adapt to cellular and systemic signals to homeostatically regulate ion transport. Over 100 000 post-translational modifications have been identified in the human proteome, with major categories that include glycosylation, lipidation, phosphorylation, and ubiquitination. 38 Post-translational modifications can occur in isolation or in a coordinated network, 39 as described for ZIP14 20 and, possibly, other ubiquitinated trace mineral transporters ( Table 1) . Ubiquitination of trace mineral transporters is an emerging area of interest.
Ubiquitination is a highly regulated process conserved in all eukaryotes. The process involves the covalent attachment of ubiquitin, a 76-amino acid polypeptide, to lysine residues. Ubiquitin conjugation occurs by enzymatic cascades involving 3 general classes of ubiquitin enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s). Deubiquitinases can modify existing ubiquitin modifications and can, for example, rescue a target protein from degradation by removing a degradative ubiquitin signal and enhancing its stability. 40 There are several types of ubiquitin modification, and these are thought to have different effects on target proteins. Monoubiquitination is thought to regulate intracellular and plasma membrane trafficking of membrane proteins and receptors. 41 Polyubiquitination (i.e., the conjugation of 4 or more ubiquitin moieties) selectively targets proteins for degradation by the proteasome or lysosome. The polyubiquitin chain begins with an isopeptide bond between the diglycine carboxyl group (G 75 G) of ubiquitin and the e-amino group of a lysine residue, or, less commonly, with the amino group at the N-terminus of a target protein. whereas substrates with K 63 -linked ubiquitin chains are generally not degraded and are essential components for endocytic trafficking, the inflammatory response, protein translation, and DNA repair. 42 Two main ubiquitination pathways exist (Figure 1) . Secretory proteins and plasma membrane proteins that fail quality control mechanisms in the endoplasmic reticulum are selectively retrotranslocated into the cytosol, ubiquitinated, and degraded by the 26S proteasome. The proteasome is found in the cytosol and consists of a 20S barrel-shaped catalytic core containing multiple proteolytic sites and a 19S regulatory component that governs entry to the core. Alternatively, ubiquitin binding to plasma membrane proteins at the cell surface can mediate the endocytosis of membrane proteins, followed by sorting into late endosomes/multivesicular bodies and recycling back to the cell surface or delivery to lysosomes for degradation. It is important to note that ubiquitin does not always serve as an internalization signal, as ubiquitin has been shown to be a secondary or redundant signal for some cell surface proteins by interacting with other adaptor-binding motifs. 43 
EFFECTS OF UBIQUITINATION ON TRACE MINERAL TRANSPORTER FUNCTION
Early observations of ubiquitination of membrane proteins were made in yeast (Saccharomyces cerevisiae), with the first demonstration of the ubiquitination of a trace mineral transporter in 2000. 44, 45 Early studies demonstrated that zinc exposure induces the ubiquitination of the yeast Zrt1 zinc transporter at K
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, which signals for endocytosis and degradation in the vacuole. This provides an important protective mechanism against zinc toxicity by rapidly downregulating zinc uptake in response to high levels of zinc. Since its initial discovery, ZIP4 has been demonstrated to be regulated by zinc-induced ubiquitination in a similar manner, 15 and hepcidin, a negative regulator of iron absorption, is thought to reduce intestinal absorption of iron through ubiquitination of DMT1 9 and ferroportin. 21, 22 A summary of studies identifying the ubiquitination of mammalian iron and zinc transporters can be found in Table 1 . As is evident from the table, not all ubiquitinconjugated proteins follow the canonical ubiquitination pathways. 46 Exciting recent advances have uncovered novel ubiquitin-dependent trafficking pathways and sorting steps.
Recent work demonstrates a novel pathway by which ZIP14 is ubiquitinated and degraded. 20 Similar to the transmembrane topology of other ZIP proteins, ZIP14 is predicted to have 8 transmembrane domains with extracytoplasmic N-and C-termini (Figure 2 ). 47 ZIP14 is localized to the plasma membrane and endosomal compartments and is expressed ubiquitously, with the highest levels found in the liver, heart, and pancreas. [47] [48] [49] [50] These are tissues that accumulate iron during times of iron overload, suggesting a link between iron and ZIP14. Indeed, ZIP14 was originally identified as a zinc importer 47 ; however, recent work indicates that ZIP14 also mediates transferrin-and nontransferrin-bound iron uptake into cells. 48, 50 Although the precise series of events in the newly identified degradation pathway are not known, cell surface ZIP14 is ubiquitinated, endocytosed, and degraded by the proteasome in response to low iron (Figure 1) . Conversely, iron supplementation prevents the endocytosis and degradation of ZIP14. This provides a rapid and targeted mechanism to redirect iron away from storage tissues during times of iron deficiency, thereby increasing iron availability for iron-requiring functions.
There are many unique aspects of the ZIP14 degradation pathway that may contribute to a theoretical framework that can be applied to other ubiquitinated trace mineral transporters. Perhaps most interesting is that the ubiquitination of ZIP14 is regulated by iron. ZIP14 is a member of the LIV-1 subfamily, members of which are all distinguished by a highly conserved HEXPHEXGD region in transmembrane domain V. The function of this motif is not known; however, the first histidine of this motif in ZIP14 is replaced by glutamic acid (E 376 EFPHELGD; Figure 2 ), which is thought to bind and transport other trace minerals, including iron, cadmium, and manganese. 51, 52 In addition, like many zinc transporters, ZIP14 contains a histidine-rich region (H 251 HHGHSH) between transmembrane domains III and IV (Figure 2 ) that is thought to bind zinc. This suggests that these findings may have implications for cellular uptake of other minerals besides iron, such as zinc; however, this possibility remains to be determined.
Another unique aspect of ZIP14 degradation is the pathway itself. Canonical trafficking routes of plasma membrane proteins targeted for degradation are through endocytosis and trafficking to lysosomes or through retrograde trafficking to the endoplasmic reticulum and the proteasome. The recently identified degradation pathway suggests that ZIP14 must be selectively retrotranslocated from the endosomal membrane to the cytosol for proteasomal degradation Figure 1 Ubiquitination pathways and the fate of ZIP14 in response to high and low iron concentrations [Fe] in tissues such as the liver, heart, and pancreas. The low [Fe] panel depicts the degradation pathway for ZIP14 in gray arrows. Whether cytosolic ZIP14 is deglycosylated and subsequently ubiquitinated or whether it is ubiquitinated at the plasma membrane, which signals for its endocytosis and subsequent degradation, is not known. The black arrows depict the traditional ubiquitin-mediated degradation pathways (proteasomal, dashed arrow; lysosomal, solid arrow). Details are included in the text. Abbreviations: 26S, 26S proteasome; ER, endoplasmic reticulum; Fe, iron; Ft, ferritin; LE, late endosome; Ly, lysosome; MVB, multivesicular body; N, nucleus.
( Figure 1 ). This would be the first identification of a multitransmembrane protein to participate in such a pathway 20 and may provide a mechanism whereby ZIP14 can be sorted and recycled prior to extraction from the endosomal membrane.
ZIP14 contains a long extracellular N-terminus containing at least 3 asparagine (N)-linked glycosylation sites (N 77 , N 87 , and N 102 ) ( Figure 2 ). 20 Interestingly, degradation of endocytosed ZIP14 is also dependent on the glycosylation status of ZIP14 at N 102 . The process of deglycosylation is standard for misfolded membrane and secretory proteins that are retrotranslocated from the endoplasmic reticulum to the cytosol: oligosaccharides are removed from misfolded proteins once they reach the cytosol by an N-glycanase, and deglycosylated proteins are ubiquitinated and degraded in the proteasome. However, the precise series of events in the recently identified degradation pathway for ZIP14 remains to be determined. For example, whether cytosolic ZIP14 is deglycosylated and subsequently ubiquitinated or whether it is ubiquitinated at the plasma membrane, which signals for its endocytosis and subsequent degradation, is not known. Interestingly, many of the ubiquitinated trace mineral transporters are glycosylated at the plasma membrane (Table 1) , suggesting that deglycosylation or modulation of other post-translational modifications, such as phosphorylation or lipidation, may be a common signal for internalization of these proteins.
Many other important details of the ZIP14 degradation pathway remain to be elucidated. For example, the nature of the ubiquitin attachments (mono-vs polyubiquitination) and the specific ubiquitin (e.g., K 48 Figure 2) ; however, deletion of the second intracellular loop does not have an effect on iron-stimulated degradation. 20 One possibility is that ZIP14 must be deglycosylated prior to ubiquitination, which induces a conformational change that uncovers a ubiquitination site in the N-terminus. Other important considerations include the factors that regulate ubiquitination of trace mineral transporters. Most reports demonstrate that substrate concentration (i.e., iron or zinc) regulates the rate of ubiquitination, with both high and low concentrations of iron or zinc signaling for the ubiquitination of their respective transporters (Table 1) . Moreover, Seo et al. 13 recently demonstrated that the lactogenic hormone prolactin regulates the ubiquitination of the zinc exporter ZnT2 in mammary epithelial cells. They found that ubiquitination first increased zinc secretion by trafficking ZnT2 to the plasma membrane and subsequently signaled for its endocytosis and proteasomal degradation. Stimuli released in response to substrate concentrations or inflammation, such as the peptide hormone hepcidin, have also been demonstrated to regulate the ubiquitination of iron transporters, specifically ferroportin 22 and DMT1. 9 Overall, a better understanding of the ubiquitination pathway and regulator(s) of ZIP14 and other trace mineral transporters may facilitate the development of novel therapeutic targets for the treatment of diseases associated with altered trace mineral metabolism.
CLINICAL SIGNIFICANCE
Membrane proteins represent approximately one-third of the total proteome and two-thirds of all current therapeutic targets. 53 With ubiquitination emerging as a common and effective mode of regulation for nutrient transporters comes the possibility for novel therapeutic targets. Indeed, small molecule inhibitors that target the ubiquitin proteasome system (e.g., E1s-E3s, deubiquitinases, and the proteasome itself) or other factors that regulate ubiquitination are currently in development. Recent research demonstrates that ZIP13 protein and intracellular zinc levels are restored in cells treated with bortezomib, a proteasome inhibitor approved by the US Food and Drug Administration (FDA). 17 This suggests that bortezomib may be an effective treatment for individuals with spondylocheiro dysplastic Ehlers-Danlos syndrome, a rare inherited connective tissue disorder caused by loss-of-function mutations in ZIP13. However, the effectiveness of bortezomib in treating individuals with spondylocheiro dysplastic Ehlers-Danlos syndrome and the potential efficacy of similar therapies in the treatment of various other conditions related to iron or zinc transport have yet to be fully explored.
Moving forward, targeting the ZIP14 ubiquitination pathway may be an effective means to regulate the distribution of iron in the body. The tissue expression profile of ZIP14 (i.e., liver, pancreas, heart) suggests that this protein confers an important role in the pathology of iron overload. Individuals with hereditary hemochromatosis due to mutations in the HFE gene develop iron overload in the liver, pancreas, and heart, resulting in liver cirrhosis, diabetes, and heart failure. Evidence suggests that HFE regulates iron loading in hepatocytes by controlling ZIP14 turnover. 54 If the downregulation in ZIP14 is mediated through ubiquitination of ZIP14, creating agonists that promote the ubiquitination of ZIP14 may provide a means to effectively treat iron overload.
Finally, the identification of factors that regulate ubiquitination of specific trace mineral transporters may provide further therapeutic targets. As discussed above, hepcidin is induced by inflammation and stimulates the ubiquitination of ferroportin and DMT1. This suggests that inflammatory conditions that result in hypoferremia, such as infection or obesity, [55] [56] [57] may be associated with reduced iron absorption due to ubiquitination of ferroportin and/or DMT1. Recently, fursultiamine, an FDA-approved thiamine derivative, was identified as a small molecule antagonist that blocks hepcidin-induced ubiquitination and degradation of ferroportin, 58 potentially providing an alternative treatment option for patients with anemia of inflammation. Inflammatory stimuli also regulate zinc transporters, including ZIP14 59 and ZnT2, 60 and inflammation is known to result in hypozincemia. [61] [62] [63] No report to date, however, has identified the ubiquitination of a zinc transporter in response to inflammatory stimuli. Further research is required to determine the potential link between inflammatory conditions, the ubiquitination of trace mineral transporters, and reduced mineral status.
CONCLUSION
Recent evidence suggests that post-translational modification of trace mineral transporters by ubiquitination is an important pathway to efficiently regulate uptake or efflux of minerals in a rapid manner. Moreover, targeted therapeutic intervention is an emerging area in the treatment of acute and chronic human disease. The identification of trace mineral transporters that are ubiquitinated, the subtleties of these pathways, and the factors that regulate ubiquitination will be critical in the development of new therapies. Fully understanding the role of post-translational modification in the regulation of nutrient transport and how this pathway can be harnessed may result in novel targeted therapies for the treatment of human diseases related to dysregulated trace mineral metabolism.
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